唑来膦酸注射液对原发性骨质疏松患者体温的影响

Influence of Zoledronic Acid Injection on Body Temperature of Patients with Primary Osteoporosis

目的探讨唑来膦酸注射液治疗原发性骨质疏松患者体温变化和预防用药的影响及方式选择。方法回顾性调查北京大学人民医院2013—2014年使用唑来膦酸注射液治疗的原发性骨质疏松患者共142例,查阅并记录患者用药前一天及用药后不同时间的体温,采用SPSS17.0版统计软件进行数据处理。结果静脉滴注唑来膦酸注射液后不同时间患者体温差异有统计学意义(P=0.000),预防使用非甾体类抗炎药(NSAIDs),可显著降低唑来膦酸注射液使用后第2天患者体温。结论预防使用NSAIDs从静脉滴注唑来膦酸当天开始,连续3 d口服给药为宜。

ObjectiveTo investigate the influence of zoledronic acid injection on body temperature of patients with primary osteoporosis. MethodsA total of 142 patients with primary osteoporosis who received intravenous zoledronic acid treatment in Peking university people’s hospital during 2013-2014 were enrolled in this study. The body temperature before and after intravenous zoledronic acid treatment were recorded and analyzed with SPSS 17.0 software. ResultsThe patients＇ body temperature at different time points after intravenous zoledronic acid treatment was significantly different （P=0.000）. Prophylactic use of NSAIDs could significantly reduce patients＇ body temperature at the second day after intravenous zoledronic acid. ConclusionNSAIDs can be given orally on the same day of intravenous injection of zoledronic acid, and continued for three days.